- Home
- AG vs AKRO Comparison
AG vs AKRO Comparison
Compare AG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- AKRO
- Stock Information
- Founded
- AG 1979
- AKRO 2017
- Country
- AG Canada
- AKRO United States
- Employees
- AG N/A
- AKRO N/A
- Industry
- AG Precious Metals
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- AG Basic Materials
- AKRO Health Care
- Exchange
- AG Nasdaq
- AKRO Nasdaq
- Market Cap
- AG 4.0B
- AKRO 3.6B
- IPO Year
- AG N/A
- AKRO 2019
- Fundamental
- Price
- AG $10.55
- AKRO $43.46
- Analyst Decision
- AG Strong Buy
- AKRO Strong Buy
- Analyst Count
- AG 3
- AKRO 8
- Target Price
- AG $10.67
- AKRO $80.38
- AVG Volume (30 Days)
- AG 20.4M
- AKRO 945.4K
- Earning Date
- AG 11-06-2025
- AKRO 11-07-2025
- Dividend Yield
- AG 0.19%
- AKRO N/A
- EPS Growth
- AG N/A
- AKRO N/A
- EPS
- AG 0.04
- AKRO N/A
- Revenue
- AG $826,595,000.00
- AKRO N/A
- Revenue This Year
- AG $91.40
- AKRO N/A
- Revenue Next Year
- AG N/A
- AKRO N/A
- P/E Ratio
- AG $275.51
- AKRO N/A
- Revenue Growth
- AG 61.34
- AKRO N/A
- 52 Week Low
- AG $5.09
- AKRO $21.34
- 52 Week High
- AG $10.82
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- AG 70.81
- AKRO 36.83
- Support Level
- AG $9.06
- AKRO $42.56
- Resistance Level
- AG $9.57
- AKRO $46.18
- Average True Range (ATR)
- AG 0.46
- AKRO 1.80
- MACD
- AG 0.12
- AKRO -0.19
- Stochastic Oscillator
- AG 86.73
- AKRO 13.42
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.